HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib

被引：0
|
作者：
Garrett, Joan T. [1 ]
Becker, Jennifer [1 ]
Estrada, Monica Valeria [1 ]
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-LB-212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-212
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer
    Massard, C.
    Brain, E.
    Dunan, A.
    Mathieu, M.
    Guinebretiere, J.
    Abuin, G. Gomez
    Floiras, J.
    Spielmann, M.
    Delaloge, S.
    Andre, F.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 120
  • [42] TEACH phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-overexpressing breast cancer
    Moy, B.
    Maltzman, J. D.
    Rappold, E.
    Finkelstein, D.
    Williams, L. S.
    Goss, P. E.
    EJC SUPPLEMENTS, 2008, 6 (07): : 120 - 121
  • [43] Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review
    Yip, Adrian Yun-San
    Tse, Lap-Ah
    Ong, Eleanor Yuen-Yuen
    Chow, Louis Wing-Cheong
    ANTI-CANCER DRUGS, 2010, 21 (05) : 487 - 493
  • [44] HER2 down-modulation increases sensitivity to trastuzumab in HER2-overexpressing breast cancer cells
    Valabrega, Giorgio
    Montemurro, Filippo
    Aglietta, Massimo
    Giordano, Silvia
    ANNALS OF ONCOLOGY, 2005, 16 : 30 - 30
  • [45] Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
    Rohit Singh
    Woo Jin Kim
    Pyeung-Hyeun Kim
    Hyo Jeong Hong
    Experimental & Molecular Medicine, 2013, 45 : e52 - e52
  • [46] Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
    Singh, Rohit
    Kim, Woo Jin
    Kim, Pyeung-Hyeun
    Hong, Hyo Jeong
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2013, 45 : e52 - e52
  • [47] Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
    Burstein, Harold J.
    Keshaviah, Aparna
    Baron, Ari D.
    Hart, Ronald D.
    Lambert-Falls, Rosemary
    Marcom, P. Kelly
    Gelman, Rebecca
    Winer, Eric P.
    CANCER, 2007, 110 (05) : 965 - 972
  • [48] NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells
    Yang, Liuting
    Li, Yingying
    Shen, Enyun
    Cao, Fengqi
    Li, Li
    Li, Xiaojin
    Wang, Xuejiang
    Kariminia, Seyed
    Chang, Bingmei
    Li, Hongzhong
    Li, Qin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (05) : 1553 - 1562
  • [49] Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
    Fiszman, Gabriel L.
    Jasnis, Maria A.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2011, 2011
  • [50] Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC).
    Bangemann, N
    Kuhle, A
    Ebert, A
    Bühler, H
    Schaller, G
    ANNALS OF ONCOLOGY, 2000, 11 : 143 - 143
12345